Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy
Sung-Whan Kim1, Hyongbum Kim, Young-sup Yoon
1Department of Cardiology, College of Medicine, Dong-A University, Busan, South Korea.
Insights
Bone marrow cells show potential for cardiovascular repair post-myocardial infarction. CD31+ cells, identified by a specific marker, exhibit significant therapeutic and angio-vasculogenic effects.
Area of Science:
- Regenerative Medicine
- Cardiovascular Biology
- Cell Therapy
Background:
- Bone marrow (BM)-derived cells are investigated for cardiovascular tissue regeneration after myocardial infarction.
- Clinical trials yield controversial results regarding cardiac tissue recovery.
- Cell-based therapy mechanisms are increasingly understood to involve paracrine and humoral effects, not solely tissue generation.
Purpose of the Study:
- To review recent advances in the therapeutic applications of BM-derived cells.
- To highlight the potential of specific BM cell populations, particularly CD31+ cells.
- To discuss the identification and therapeutic utility of BM-derived CD31+ cells.
Main Methods:
- Review of recent scientific literature on BM cell therapy for cardiovascular diseases.
- Focus on studies identifying cell surface markers for enhanced therapeutic effects.
- Isolation and characterization of BM-derived CD31+ cells.
Main Results:
- BM-derived cells have shown potential in cardiovascular repair.
- The therapeutic efficacy of cell therapy is linked to paracrine and humoral factors.
- BM-derived CD31+ cells demonstrate significant angio-vasculogenic properties.
Conclusions:
- BM-derived CD31+ cells represent a promising cell population for cardiovascular regeneration.
- Targeting specific cell populations like CD31+ cells may optimize cell-based therapies.
- Further research into CD31+ cell mechanisms can advance cardiac repair strategies.
Abstract:
In the past few years, bone marrow (BM)-derived cells have been used to regenerate damaged cardiovascular tissues post-myocardial infarction. Recent clinical trials have shown controversial results in recovering damaged cardiac tissue. New progress has shown that the underlying mechanisms of cell-based therapy relies more heavily on humoral and paracrine effects rather than on new tissue generation. However, studies have also reported the potential of new endothelial cell generation from BM cells. Thus, efforts have been made to identify cells having higher humoral or therapeutic effects as well as their surface markers. Specifically, BM-derived CD31+ cells were isolated by a surface marker and demonstrated high angio-vasculogenic effects. This article will describe recent advances in the therapeutic use of BM-derived cells and the usefulness of CD31+ cells.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...